Financhill
Sell
36

RGEN Quote, Financials, Valuation and Earnings

Last price:
$127.63
Seasonality move :
5.84%
Day range:
$123.25 - $126.38
52-week range:
$102.97 - $182.52
Dividend yield:
0%
P/E ratio:
633.44x
P/S ratio:
10.92x
P/B ratio:
3.57x
Volume:
867.1K
Avg. volume:
914.7K
1-year change:
-26.61%
Market cap:
$7.1B
Revenue:
$634.4M
EPS (TTM):
-$0.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RGEN
Repligen
$163.8M $0.35 9.93% 286.84% $183.13
BAX
Baxter International
$2.6B $0.48 -25.95% 590.29% $38.68
CATX
Perspective Therapeutics
$143.9K -$0.27 -- -55.87% $13.8214
ICUI
ICU Medical
$574.2M $1.28 -8.91% 316.67% $186.20
MASS
908 Devices
$11.9M -$0.27 -11.42% -63.51% $5.50
UFPT
UFP Technologies
$139.9M $2.01 37.56% 28.57% $311.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RGEN
Repligen
$126.19 $183.13 $7.1B 633.44x $0.00 0% 10.92x
BAX
Baxter International
$31.47 $38.68 $16.1B 167.20x $0.17 2.92% 1.36x
CATX
Perspective Therapeutics
$2.7300 $13.8214 $202.6M -- $0.00 0% 19.24x
ICUI
ICU Medical
$138.00 $186.20 $3.4B -- $0.00 0% 1.40x
MASS
908 Devices
$4.77 $5.50 $171.1M -- $0.00 0% 2.70x
UFPT
UFP Technologies
$241.89 $311.00 $1.9B 29.61x $0.00 0% 3.44x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RGEN
Repligen
21.06% 1.369 7.41% 5.56x
BAX
Baxter International
58.72% 0.052 57.45% 1.13x
CATX
Perspective Therapeutics
-- -1.032 -- --
ICUI
ICU Medical
43.6% 1.698 44.96% 0.90x
MASS
908 Devices
-- -5.739 -- 6.71x
UFPT
UFP Technologies
33.63% 3.826 11.76% 1.39x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RGEN
Repligen
$90.8M $6.6M -0.91% -1.16% 7.8% $10.6M
BAX
Baxter International
$861M $58M -2.78% -7.38% 2.97% -$315M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
ICUI
ICU Medical
$210.1M $29.6M -2.6% -4.64% 2.37% $34.5M
MASS
908 Devices
$5.5M -$8.5M -12.31% -12.31% -72.4% -$15.2M
UFPT
UFP Technologies
$42.2M $23.4M 13.85% 19.38% 15.59% $11M

Repligen vs. Competitors

  • Which has Higher Returns RGEN or BAX?

    Baxter International has a net margin of 3.45% compared to Repligen's net margin of 4.8%. Repligen's return on equity of -1.16% beat Baxter International's return on equity of -7.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    53.65% $0.10 $2.5B
    BAX
    Baxter International
    32.8% $0.25 $17.1B
  • What do Analysts Say About RGEN or BAX?

    Repligen has a consensus price target of $183.13, signalling upside risk potential of 45.12%. On the other hand Baxter International has an analysts' consensus of $38.68 which suggests that it could grow by 22.91%. Given that Repligen has higher upside potential than Baxter International, analysts believe Repligen is more attractive than Baxter International.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    10 5 0
    BAX
    Baxter International
    4 11 1
  • Is RGEN or BAX More Risky?

    Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison Baxter International has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.167%.

  • Which is a Better Dividend Stock RGEN or BAX?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.92% to investors and pays a quarterly dividend of $0.17 per share. Repligen pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or BAX?

    Repligen quarterly revenues are $169.2M, which are smaller than Baxter International quarterly revenues of $2.6B. Repligen's net income of $5.8M is lower than Baxter International's net income of $126M. Notably, Repligen's price-to-earnings ratio is 633.44x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 10.92x versus 1.36x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    10.92x 633.44x $169.2M $5.8M
    BAX
    Baxter International
    1.36x 167.20x $2.6B $126M
  • Which has Higher Returns RGEN or CATX?

    Perspective Therapeutics has a net margin of 3.45% compared to Repligen's net margin of --. Repligen's return on equity of -1.16% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    53.65% $0.10 $2.5B
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About RGEN or CATX?

    Repligen has a consensus price target of $183.13, signalling upside risk potential of 45.12%. On the other hand Perspective Therapeutics has an analysts' consensus of $13.8214 which suggests that it could grow by 406.28%. Given that Perspective Therapeutics has higher upside potential than Repligen, analysts believe Perspective Therapeutics is more attractive than Repligen.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    10 5 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is RGEN or CATX More Risky?

    Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

  • Which is a Better Dividend Stock RGEN or CATX?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or CATX?

    Repligen quarterly revenues are $169.2M, which are larger than Perspective Therapeutics quarterly revenues of --. Repligen's net income of $5.8M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Repligen's price-to-earnings ratio is 633.44x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 10.92x versus 19.24x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    10.92x 633.44x $169.2M $5.8M
    CATX
    Perspective Therapeutics
    19.24x -- -- -$18.2M
  • Which has Higher Returns RGEN or ICUI?

    ICU Medical has a net margin of 3.45% compared to Repligen's net margin of -2.56%. Repligen's return on equity of -1.16% beat ICU Medical's return on equity of -4.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    53.65% $0.10 $2.5B
    ICUI
    ICU Medical
    34.75% -$0.63 $3.5B
  • What do Analysts Say About RGEN or ICUI?

    Repligen has a consensus price target of $183.13, signalling upside risk potential of 45.12%. On the other hand ICU Medical has an analysts' consensus of $186.20 which suggests that it could grow by 34.93%. Given that Repligen has higher upside potential than ICU Medical, analysts believe Repligen is more attractive than ICU Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    10 5 0
    ICUI
    ICU Medical
    3 1 0
  • Is RGEN or ICUI More Risky?

    Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison ICU Medical has a beta of 0.870, suggesting its less volatile than the S&P 500 by 12.976%.

  • Which is a Better Dividend Stock RGEN or ICUI?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or ICUI?

    Repligen quarterly revenues are $169.2M, which are smaller than ICU Medical quarterly revenues of $604.7M. Repligen's net income of $5.8M is higher than ICU Medical's net income of -$15.5M. Notably, Repligen's price-to-earnings ratio is 633.44x while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 10.92x versus 1.40x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    10.92x 633.44x $169.2M $5.8M
    ICUI
    ICU Medical
    1.40x -- $604.7M -$15.5M
  • Which has Higher Returns RGEN or MASS?

    908 Devices has a net margin of 3.45% compared to Repligen's net margin of -103.33%. Repligen's return on equity of -1.16% beat 908 Devices's return on equity of -12.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    53.65% $0.10 $2.5B
    MASS
    908 Devices
    47.05% $1.23 $159.4M
  • What do Analysts Say About RGEN or MASS?

    Repligen has a consensus price target of $183.13, signalling upside risk potential of 45.12%. On the other hand 908 Devices has an analysts' consensus of $5.50 which suggests that it could grow by 15.3%. Given that Repligen has higher upside potential than 908 Devices, analysts believe Repligen is more attractive than 908 Devices.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    10 5 0
    MASS
    908 Devices
    3 1 0
  • Is RGEN or MASS More Risky?

    Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison 908 Devices has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock RGEN or MASS?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 908 Devices offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. 908 Devices pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or MASS?

    Repligen quarterly revenues are $169.2M, which are larger than 908 Devices quarterly revenues of $11.8M. Repligen's net income of $5.8M is lower than 908 Devices's net income of $43.6M. Notably, Repligen's price-to-earnings ratio is 633.44x while 908 Devices's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 10.92x versus 2.70x for 908 Devices. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    10.92x 633.44x $169.2M $5.8M
    MASS
    908 Devices
    2.70x -- $11.8M $43.6M
  • Which has Higher Returns RGEN or UFPT?

    UFP Technologies has a net margin of 3.45% compared to Repligen's net margin of 11.6%. Repligen's return on equity of -1.16% beat UFP Technologies's return on equity of 19.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGEN
    Repligen
    53.65% $0.10 $2.5B
    UFPT
    UFP Technologies
    28.45% $2.21 $543.4M
  • What do Analysts Say About RGEN or UFPT?

    Repligen has a consensus price target of $183.13, signalling upside risk potential of 45.12%. On the other hand UFP Technologies has an analysts' consensus of $311.00 which suggests that it could grow by 28.57%. Given that Repligen has higher upside potential than UFP Technologies, analysts believe Repligen is more attractive than UFP Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    RGEN
    Repligen
    10 5 0
    UFPT
    UFP Technologies
    1 2 0
  • Is RGEN or UFPT More Risky?

    Repligen has a beta of 1.207, which suggesting that the stock is 20.699% more volatile than S&P 500. In comparison UFP Technologies has a beta of 1.100, suggesting its more volatile than the S&P 500 by 9.979%.

  • Which is a Better Dividend Stock RGEN or UFPT?

    Repligen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UFP Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen pays -- of its earnings as a dividend. UFP Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGEN or UFPT?

    Repligen quarterly revenues are $169.2M, which are larger than UFP Technologies quarterly revenues of $148.1M. Repligen's net income of $5.8M is lower than UFP Technologies's net income of $17.2M. Notably, Repligen's price-to-earnings ratio is 633.44x while UFP Technologies's PE ratio is 29.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen is 10.92x versus 3.44x for UFP Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGEN
    Repligen
    10.92x 633.44x $169.2M $5.8M
    UFPT
    UFP Technologies
    3.44x 29.61x $148.1M $17.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Ginkgo Bioworks Stock a Good Buy?
Is Ginkgo Bioworks Stock a Good Buy?

Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…

Why Mobileye Might Be Wall Street’s Next Big Surprise
Why Mobileye Might Be Wall Street’s Next Big Surprise

The trend to automate vehicles started long ago when adding…

Why Is Rigetti Stock Going Up?
Why Is Rigetti Stock Going Up?

Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
99
SOC alert for May 20

Sable Offshore [SOC] is down 0.79% over the past day.

Buy
52
RGC alert for May 20

Regencell Bioscience Holdings [RGC] is up 31.16% over the past day.

Sell
40
GWLIF alert for May 20

Great-West Lifeco [GWLIF] is up 13.42% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock